https://www.selleckchem.com/pr....oducts/durvalumab.ht
2 mL blood. The median progression-free survival (PFS) was 43.1 months. Patients in which CTCs were detected had a significantly shorter PFS than CTC-negative patients (P = 0.018). Multivariate analysis indicated that CTC count was an independent negative prognostic factor for survival. However, no correlation was observed between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. CTC count is an independent negative prognostic factor for cervical cancer. CTC count is an indepen
Curtir
Comentario
Compartilhar
